Literature DB >> 9765493

Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.

T M Karnauchow1, S Dawe, D M Lublin, K Dimock.   

Abstract

Enterovirus 70 (EV70), like several other human enteroviruses, can utilize decay-accelerating factor (DAF [CD55]) as an attachment protein. Using chimeric molecules composed of different combinations of the short consensus repeat domains (SCRs) of DAF and membrane cofactor protein (CD46), we show that sequences in SCR1 of DAF are essential for EV70 binding. Of the human enteroviruses that can bind to DAF, only EV70 and coxsackievirus A21 require sequences in SCR1 for this interaction.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9765493      PMCID： PMC110365     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Decay-accelerating factor and membrane cofactor protein.

Authors:  D M Lublin; J P Atkinson
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Authors:  T R Fuerst; E G Niles; F W Studier; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

3.  Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21.

Authors:  D R Shafren; D J Dorahy; S J Greive; G F Burns; R D Barry
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  A 44,000 glycoprotein is involved in the attachment of echovirus-11 onto susceptible cells.

Authors:  A D Mbida; B Pozzetto; O G Gaudin; F Grattard; J C Le Bihan; Y Akono; A Ros
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

5.  Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.

Authors:  K E Coyne; S E Hall; S Thompson; M A Arce; T Kinoshita; T Fujita; D J Anstee; W Rosse; D M Lublin
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

6.  Replication of enterovirus 70 in non-primate cell cultures.

Authors:  T Yoshii; K Natori; R Kono
Journal:  J Gen Virol       Date:  1977-09       Impact factor: 3.891

7.  A monoclonal antibody recognizes a human cell surface glycoprotein involved in measles virus binding.

Authors:  D Naniche; T F Wild; C Rabourdin-Combe; D Gerlier
Journal:  J Gen Virol       Date:  1992-10       Impact factor: 3.891

8.  Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.

Authors:  M E Medof; D M Lublin; V M Holers; D J Ayers; R R Getty; J F Leykam; J P Atkinson; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

9.  Monoclonal antibody specific for the cellular receptor of echoviruses.

Authors:  A D Mbida; O G Gaudin; O Sabido; B Pozzetto; J C Le Bihan
Journal:  Intervirology       Date:  1992       Impact factor: 1.763

10.  Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.

Authors:  D M Lublin; K E Coyne
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307
View more
  19 in total

1.  Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

Authors:  Geoffrey Gifford; Vivian P Vu; Nirmal K Banda; V Michael Holers; Guankui Wang; Ernest V Groman; Donald Backos; Robert Scheinman; S Moein Moghimi; Dmitri Simberg
Journal:  J Control Release       Date:  2019-04-08       Impact factor: 9.776

Review 2.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Sialic acid functions in enterovirus 70 binding and infection.

Authors:  David A Alexander; Kenneth Dimock
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli.

Authors:  R Selvarangan; P Goluszko; V Popov; J Singhal; T Pham; D M Lublin; S Nowicki; B Nowicki
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

5.  Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.

Authors:  E Susanne Johansson; Li Xing; R Holland Cheng; Darren R Shafren
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55.

Authors:  Sylvie Hudault; O Brad Spiller; B Paul Morgan; Alain L Servin
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.

Authors:  Nicole G Newcombe; E Susanne Johansson; Gough Au; A Michael Lindberg; Richard D Barry; Darren R Shafren
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Interaction of decay-accelerating factor with coxsackievirus B3.

Authors:  Susan Hafenstein; Valorie D Bowman; Paul R Chipman; Carol M Bator Kelly; Feng Lin; M Edward Medof; Michael G Rossmann
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

9.  Binding to decay-accelerating factor is not required for infection of human leukocyte cell lines by enterovirus 70.

Authors:  Alain Haddad; M Reza Nokhbeh; David A Alexander; Sandra J Dawe; Christine Grisé; Naveed Gulzar; Kenneth Dimock
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR.

Authors:  Nina Jonsson; Maria Gullberg; Stina Israelsson; A Michael Lindberg
Journal:  Virol J       Date:  2009-12-07       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.